Shrydus Industries Limited (formerly **VCK Capital Market Services Limited**) is an Indian listed entity undergoing a fundamental strategic transformation. Historically a financial services firm and Merchant Banker, the company surrendered its license in **2012** and has since pivoted toward a diversified industrial model. Today, Shrydus is aggressively expanding into **Pharmaceutical Manufacturing**, **Civil Construction**, and **International Commodity Trading**, supported by a significantly restructured capital base and a shift in corporate identity. --- ### **Strategic Pivot: High-Growth Business Verticals** The company is transitioning from a pure trading model to an asset-heavy industrial conglomerate through the following key initiatives: #### **1. Pharmaceutical Manufacturing & Global Exports** Shrydus is in the final stages of acquiring **100% ownership** of **Astra Lifecare (India) Private Limited** for an estimated **Rs. 15.68 crore**. This acquisition transforms the company into a manufacturer with a global footprint. * **Infrastructure:** A **WHO-GMP certified**, **100% Export Oriented Unit (EOU)** in Gujarat spanning **19,013 Sq. Meters**. * **Production Capacity:** * **Tablets:** **2 Crore (20 Mn) units per day** * **Capsules:** **0.4 Crore (4 Mn) units per day** * **Product Portfolio:** Over **400 registered products** (Antibiotics, Anti-malarial, Cardiovascular) and **250+ international registrations**. * **Market Reach:** Established presence in East Africa (**Uganda, Tanzania, Kenya, Ethiopia**) and **Sri Lanka**. * **Sustainability:** Includes a captive **3.25 MW** per annum wind power plant to offset energy costs. #### **2. Real Estate & Civil Construction** The company has entered the Mumbai redevelopment market to diversify its domestic revenue streams. * **Key Project:** Redevelopment of "**Arora House**" in Mumbai (Commenced **December 2024**). * **Contract Value:** **Rs. 98,20,000** for a **24,500 Sft** built-up area. * **Strategic Stake:** In February 2025, the Board proposed acquiring a **51% stake** in **Shrydus Realty Private Limited**. #### **3. International Trading Operations** * **UAE Expansion:** Completed the **100% acquisition** of **Roopyaa General Trading Co. L.L.C** (Dubai) in February 2025. * **Commodity Focus:** Trading in agricultural products, targeting a sector projected to reach **US$ 24 billion by 2025**. --- ### **Financial Position & Capital Restructuring** The company has executed a massive balance sheet expansion to fund its new industrial ambitions. | Financial Metric (Rs. in Lakhs) | FY 2024-25 (Audited) | FY 2023-24 (Audited) | Growth/Change | |:---|:---|:---|:---| | **Total Assets** | **4,275.62** | **1,688.81** | **+153%** | | **Total Equity / Net Worth** | **4,271.80** | **596.81** | **+615%** | | **Equity Share Capital** | **3,202.26** | **1,201.38** | **+166%** | | **Non-Current Borrowings** | **1.71** | **1,090.74** | **-99.8%** | | **Other Equity (Reserves)** | **1,069.55** | **(604.57)** | **Turnaround** | **Key Capital Actions:** * **Rights Issue (2024-25):** Allotted **2,00,08,810 Equity Shares** at **Rs. 18/-** (including **Rs. 8/- premium**) raising **Rs. 36.02 Crore**. * **Deleveraging:** Converted **Rs. 9.32 Crore** of outstanding unsecured loans from the **Promoter Group** into equity to strengthen the balance sheet. * **Authorized Capital:** Increased from **Rs. 40 Crore** to **Rs. 90 Crore** in September 2025 to facilitate future fundraising. * **Shareholding:** Promoters held **25.86%** (as of March 2024); **91.63%** of total equity is held in dematerialized form. --- ### **Operational Infrastructure & Governance Evolution** * **Corporate Identity:** Rebranded to **Shrydus Industries Limited** and relocated the Registered Office from **West Bengal** to **Maharashtra** to centralize operations. * **Technology Integration:** Implementing **AI, Machine Learning, and Predictive Analytics** for risk assessment and decision-making in the agricultural and pharma verticals. * **Internal Controls:** The Audit Committee oversees material subsidiaries; however, the company currently **does not recognize Deferred Tax Assets** due to revenue uncertainty. * **Asset Profile:** Historically an asset-light trading firm (reporting **no fixed assets** in 2023), the company is now transitioning to an asset-heavy model via the Astra Lifecare acquisition. --- ### **Risk Factors & Compliance Monitoring** Investors should note several regulatory and operational challenges associated with the company’s rapid transition: **1. Regulatory & Statutory Compliance Lapses:** * **Filing Delays:** Failure to submit **FY 2024-25** and **FY 2022-23** Annual Reports in **XBRL mode** and delays in **June 2024** quarterly results. * **Governance Gaps:** Audit Committee meeting intervals exceeded **120 days**; Independent Directors were not registered in the mandatory **IICA database**. * **Historical Qualifications:** Previous audits noted a lack of **Secretarial Audit reports** and inability to verify certain transactions due to missing **e-way bills**. **2. Operational & Market Risks:** * **Order-Based Revenue:** The business lacks long-term fixed contracts, operating on an **order-by-order basis**, which creates high revenue volatility. * **Insurance & IP:** As of July 2024, the company **held no insurance coverage** for business risks (fire/theft) and has **not registered its corporate logo** or trademarks. * **Surveillance:** The stock is classified under **GSM Stage 0 (Graded Surveillance Measure)**, necessitating cautious due diligence. * **Construction Penalties:** The "Arora House" contract carries a delay penalty of **Rs. 20,000 per day**. **3. Financial Risks:** * **Cash Flow:** The company has reported **negative cash flows** in recent periods. * **Dividend Policy:** No dividends have been paid since incorporation; profits are currently being reinvested into the expansion strategy. * **Related Party Debt:** Outstanding loans from Directors totaled **Rs. 1.54 Crore** as of March 2023. --- ### **Investment Outlook** Shrydus Industries is a **high-risk, high-reward** turnaround play. The successful integration of **Astra Lifecare** and the **UAE trading hub** could provide the manufacturing scale and international revenue needed to stabilize its volatile trading history. However, the company must address its **statutory compliance record** and **liquidity management** to gain long-term institutional confidence.